Should we consider aldosterone as the primary screening target for preventing cardiovascular events?

Journal of the American College of Cardiology

Volumn 45, Issue 8, 2005, Pages 1249-1250

  Francis, Gary S ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MORBIDITY; NOTE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SCREENING;

EID: 17144385150     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.01.014     Document Type: Editorial

References (15)

1. E.M. Freel, J.M. Connell Mechanisms of hypertension the expanding role of aldosterone J Am Soc Nephrol 15 2004 1993 2001
2. B. Pitt, F. Zannad, W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
3. B. Pitt, W. Remme, F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
4. A.D. Struthers, T.M. MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res 61 2004 663 670
5. P.M. Mottram, B. Haluska, R. Leano, D. Cowley, M. Stowasser, T.H. Marwick Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure Circulation 110 2004 558 565
6. J.E. Macdonald, N. Kennedy, A.D. Struthers Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment Heart 90 2004 765 770
7. H.R. Brunner, J.H. Laragh, L. Baer Essential hypertension renin and aldosterone, heart attack and stroke N Engl J Med 286 1972 441 449
8. M. Stowasser, R.D. Gordon Primary aldosteronism--careful investigation is essential and rewarding Mol Cell Endocrinol 217 2004 33 39
9. P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M.E. Safar, J.-J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol 45 2005 1243 1248
10. G.P. Rossi, A. Sacchetto, E. Pavan Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma Circulation 95 1997 1471 1478
11. R.S. Vasan, J.C. Evans, M.G. Larson Serum aldosterone and the incidence of hypertension in nonhypertensive persons N Engl J Med 351 2004 33 41
12. M. Stowasser New perspectives on the role of aldosterone excess in cardiovascular disease Clin Exp Pharmacol Physiol 28 2001 783 791
13. K.M. Fox Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
14. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
15. W.H. Tang, G.S. Francis Spironolactone in chronic heart failure all's well that ends well J Am Coll Cardiol 41 2003 215 216